Controversial New Alzheimer’s Drug Approved Despite Reservations
Follow via Flickr Link: https://www.flickr.com/photos/alzmglc/15311519476/in/photolist-pk2xi7-p5zz1T-pn36eW-pk2z4G-pn4Zzt-p5yHLJ-p5yCyQ-p5yy7H-p5yKrY-p5zBtP-pn2YxE-pn4BVM-p5ztkA-pmMonT-p5ziQo-bxQfpz-pmMxTM-p5zXeR-p5zbib-p5zQFk-pn3m45-pk2Tsf-p5zB8E-pn4N6g-4eGjGS-CFX1-pk2JQf-WfWjgu-pk2Lc3-3hQn2G-4kkzZx-6DojR2-51m44-7rJbFK-9YAmBr-fkWSC9-44Aksc-nSqng6-GAH7BD-j1M1Sk-gv1YhP-6Doi7x-3xK9k-6DoitF-dwaKm8-fkWSGw-6DoiYK-6DssxN-MhcFWN-o17RFw
The U.S. Food and Drug Administration has approved the first new drug for Alzheimer’s disease in 20 years, but some doctors, including one at UAB, warned patients’ families not to expect much from the drug any time soon.
The drug, aducanumab, is expected to help slow the progression of the disease, but not to improve current memory impairments, according to a release from the University of Alabama at Birmingham. The university’s Division of Memory Disorders and the Alzheimer’s Disease Center have been involved in clinical trials of aducanumab for the past five years.
“The approval of the first disease-modifying therapy is a milestone for our field and a result of years of intense research. However, it must be understood that [aducanumab] is not expected to restore memory or reverse the symptoms of Alzheimer’s disease,” said Dr. David Geldmacher, professor of neurology at UAB and clinical core director of the center. “Instead, it is expected to slow the worsening of the disease. [Aducanumab] is likely the beginning of a new era in treating AD, but not the end of the story.”
Geldmacher said it would be some time before the drug is widely available, not all patients will be eligible to receive it, and many patients, especially with advanced disease, are not likely to see improvement from it.
The FDA approved the drug despite opposition from an independent advisory committee and some Alzheimer’s experts who said there was not enough evidence the drug helps patients, according to several news reports, including from the Associated Press.
The FDA did require the drugmaker, Biogen, to conduct another study to determine whether it benefits patients, and it could pull the drug from the market if its effectiveness is not proven.
Editor’s Note: UAB holds WBHM’s broadcast license, but our news and business departments operate independently.
After the U.S. Supreme Court overturns Roe v. Wade, Republican lawmakers applaud, others say they will sue, and some take to the streets
The ACLU of Alabama say it will continue its lawsuit to reinstate access to abortion.
What to know about Alabama abortion rights after SCOTUS overturns Roe v. Wade
The U.S. Supreme Court has overturned Roe v. Wade, ending the constitutional right to an abortion. Here’s what the decision means for the Gulf South region.
Alabama OKs $725M bond sale to build 2 supersize prisons
That money will be added to $135 million in state funds and $400 million in pandemic relief dollars that the state already agreed to put toward the project.
Britt wins tumultuous Alabama Senate race scrambled by Trump
Katie Britt won the Republican nomination for Senate in Alabama Tuesday, defeating six-term Rep. Mo Brooks in a primary runoff after former President Donald Trump took the unusual step of rescinding his initial Brooks endorsement.
2022 Alabama primary runoff results
Republicans will be choosing between Katie Britt and Roy Moore as their nominee for U.S. Senate. Democrats will pick a nominee for governor between Yolonda Flowers and Malika Sanders-Fortier.
Gunman kills 3 seniors over potluck dinner at Alabama church
The suspect, 70-year-old Robert Findlay Smith, was charged with capital murder Friday. He is being held on no bond.
